IMVT Archives - Page 7 of 8

1 minute read

Immunovant’s New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say

September 29, 2:36 PM

On Wednesday, Immunovant Inc (NASDAQ:IMVT) announced a new anti-FcRn, IMVT-1402, at Roivant Sciences Ltd’s (NASDAQ:ROIV) Investor Day. IMVT-1402 is a new anti-FcRn monoclonal antibody…

ARGX

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

September 29, 1:43 PM

Gainers

ADTX

1 minute read

UBS Slashes PT On This Stock By Over 89%? Plus Evercore ISI Group Predicts $150 For First Solar

By Lisa Levin

September 29, 8:43 AM

Evercore ISI Group boosted First Solar, Inc. (NASDAQ: FSLR) price target from $88 to $150. First Solar shares rose 1.7% to $138.49 in pre-market trading.

AAPL

2 minute read

Immunovant Announces IMVT-1402, A Next Generation Anti-FcRn; Plan To Submit IND And Initiate Phase 1 Study In Early 2023 With Initial Data Expected In Mid-2023.

By Benzinga Newsdesk

September 28, 10:47 AM

In animal studies, deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein (LDL) was observed. Plan to submit IND and initiate Phase 1 study in early 2023

IMVT

1 minute read

This Analyst Slashes PT On Lyft By 68%, Plus Telsey Advisory Group Predicts $125 For Nike

By Lisa Levin

September 26, 8:28 AM

UBS cut Lyft, Inc. (NASDAQ: LYFT) price target from $50 to $16. Lyft shares fell 3.7% to $13.47 in pre-market trading.

BALL

1 minute read

Las Vegas Sands To Surge 70%? Here Are 5 Other Price Target Changes For Monday

By Lisa Levin

September 26, 7:53 AM

Citigroup raised Las Vegas Sands Corp. (NYSE: LVS) price target from $58 to $60. Citigroup analyst George Choi maintained the stock with a Buy. Las Vegas Sands shares rose 0.5% to close at $35.47 on Friday.

ADTN

1 minute read

UBS Downgrades Immunovant to Neutral, Lowers Price Target to $5

By Benzinga Newsdesk

September 26, 6:11 AM

UBS analyst Colin Bristow downgrades Immunovant (NASDAQ:IMVT) from Buy to Neutral and lowers the price target from $7 to $5.

IMVT

1 minute read

Immunovant Announces Two New Development Programs For Batoclimab

By Bill Haddad

September 7, 6:31 AM

Plan to initiate a Pivotal Phase 2b trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the second half of 20221 with initial results from open-label period 1 expected in the first half of

IMVT

6 minute read

Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday

By Lisa Levin

August 22, 2:33 AM

Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday.

ADTX

7 minute read

This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday

By Lisa Levin

August 16, 3:28 AM

Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month.

AGFY

Feed Symbols: IMVT